Want to join the conversation?
$ENDP's 1Q16 revenue grew 35% versus 1Q15 due to Auxilium and Par acquisitions. US Branded revenue grew 8.5% due to higher net sales in Specialty Pharma and Branded Other. US Generic revenue grew 63.4% due to higher net sales in US Generics Base and Sterile Injectables. International Pharma revenue fell 2% due to foreign currency rate fluctuations.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.
$KO’s CEO Muhtar Kent to step down next year. COO James Quincey will take the helm in what is already a smooth sailing scenario. And as always, shares reflect by growing 2% after the market opened.